期刊
BIOLOGICAL PSYCHIATRY
卷 74, 期 1, 页码 7-14出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2012.12.007
关键词
Antidepressant; depression; machine learning; prediction; risk stratification; selective serotonin reuptake inhibitor; treatment-resistant depression
资金
- National Institute of Mental Health [N01 MH-90003, MH086026]
- Genomind
- Healthrageous
- Pamlab
- Proteus Biomedical
- RIDVentures
Background: Early identification of depressed individuals at high risk for treatment resistance could be helpful in selecting optimal setting and intensity of care. At present, validated tools to facilitate this risk stratification are rarely used in psychiatric practice. Methods: Data were drawn from the first two treatment levels of a multicenter antidepressant effectiveness study in major depressive disorder, the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) cohort. This cohort was divided into training, testing, and validation subsets. Only clinical or sociodemographic variables available by or readily amenable to self-report were considered. Multivariate models were developed to discriminate individuals reaching remission with a first or second pharmacological treatment trial from those not reaching remission despite two trials. Results: A logistic regression model achieved an area under the receiver operating characteristic curve exceeding .71 in training, testing, and validation cohorts and maintained good calibration across cohorts. Performance of three alternative models with machine learning approaches-a naive Bayes classifier and a support vector machine, and a random forest model-was less consistent. Similar performance was observed between more and less severe depression, men and women, and primary versus specialty care sites. A web-based calculator was developed that implements this tool and provides graphical estimates of risk. Conclusion: Risk for treatment resistance among outpatients with major depressive disorder can be estimated with a simple model incorporating baseline sociodemographic and clinical features. Future studies should examine the performance of this model in other clinical populations and its utility in treatment selection or clinical trial design.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据